Cigna Drug and Biologic Coverage Policy
|
|
- Sophia Adams
- 6 years ago
- Views:
Transcription
1 Cigna Drug and Biologic Coverage Policy Subject Mecasermin Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 5 References... 5 Effective Date... 5/15/2017 Next Review Date... 4/15/2018 Coverage Policy Number Related Coverage Resources Somatropin (Genotropin, Humatrope, Norditropin, Nutropin, Nutropin AQ, Omnitrope, Saizen, Serostim, Tev- Tropin, Zorbtive ) INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna companies. Coverage Policies are intended to provide guidance in interpreting certain standard Cigna benefit plans. Please note, the terms of a customer s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations. Proprietary information of Cigna. Copyright 2017 Cigna Coverage Policy Cigna covers mecasermin (Increlex ) as medically necessary for the treatment of growth failure in children with severe primary insulin-like growth factor-1 (IGF-1) deficiency and ALL of the following: child is 2 years of age or older height standard deviation score less than or equal to 3.0 basal IGF-1 standard deviation score less than or equal to 3.0 normal or elevated growth hormone (GH) child is not concurrently treated for growth hormone deficiency (GHD) Note: Severe primary IGF-1 deficiency includes patients with mutations in the GH receptor (GHR), post- GHR signaling pathway, and IGF-1 gene defects. Cigna covers mecasermin (Increlex ) as medically necessary for the treatment of growth failure in children with growth hormone (GH) gene mutation with development of neutralizing antibodies to GH and ALL of the following: child is 2 years of age or older evidence of (GH1) gene mutation presence of GH neutralizing antibodies child is not concurrently treated for growth hormone deficiency (GHD) Page 1 of 5
2 initial criteria for growth hormone deficiency (GHD) in children were met, including BOTH of the following: o auxologic evaluation (stature and growth velocity data), including ONE of the following: individual s height is more than 2 standards of deviation (SD) below average for the population mean height for age and sex, AND a height velocity measured over one year is more than 1 SD below the mean for chronological age. individual s height velocity measured over one year is more than 2 SD below the mean for age and sex OR more than 1.5 SD below the mean sustained over two years o diagnostic evaluation, including BOTH of the following: growth hormone response of less than 10 ng/ml to at least two provocative stimuli of growth hormone release: clonidine, glucagon, insulin, L-arginine, levodopa, propranolol. One abnormal growth hormone stimulation test is sufficient for children with defined central nervous system (CNS) pathology (for example, empty sella syndrome, interruption of pituitary stalk, hypoplasia of the pituitary gland, craniofacial developmental defects, pituitary or hypothalamic tumors, etc.); multiple pituitary hormone deficiency (MPHD) (i.e., deficiency of two or more pituitary hormones) or a proven genetic defect affecting the growth hormone axis. other pituitary hormone deficiencies (for example, thyroid, cortisol or sex steroids) have been ruled out and/or corrected prior to time of testing Standard re-authorization criteria apply: Yearly reassessment for reauthorization of coverage is required. Coverage for continuation of therapy requires meeting current initial use criteria and evidence of a beneficial response as shown by growth curve chart. Coverage for growth promotion will cease when the bony epiphyses have closed. Child is not concurrently treated for growth hormone deficiency (GHD) Cigna does NOT cover mecasermin (Increlex ) for any other indication or for treatment of secondary forms of IGF-1 deficiency due to ANY of the following because it is considered experimental, investigational or unproven (this list may not be all-inclusive): GH deficiency malnutrition hypothyroidism chronic treatment with pharmacologic doses of anti-inflammatory drugs Cigna does NOT cover mecasermin (Increlex) for the diagnosis/treatment/management of the following conditions because they are considered not medically necessary (this list may not be all-inclusive): idiopathic (i.e. of unknown origin) short stature, also called non-growth hormone deficient short stature in children When coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to mecasermin (Increlex ) therapy. Note: Receipt of sample product does not satisfy any criteria requirements for coverage FDA Approved Indications Severe Primary IGF-1 Deficiency (Primary IGFD) Page 2 of 5
3 Increlex is indicated for the treatment of growth failure in children, 2 years and older, with severe primary IGF-1 deficiency or growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. Severe Primary IGF-1 deficiency (IGFD) is defined by: height standard deviation score 3.0 and basal IGF-1 standard deviation score 3.0 and normal or elevated growth hormone (GH) Severe primary IGFD includes classical and other forms of growth hormone insensitivity. Patients with primary IGFD may have mutations in the GH receptor (GHR), post-ghr signaling pathway including the IGF-1 gene. They are not GH deficient, and therefore, they cannot be expected to respond adequately to exogenous GH treatment. Increlex is not intended for use in subjects with secondary forms of IGF-1 deficiency, such as GH deficiency, malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of antiinflammatory steroids. Thyroid and nutritional deficiencies should be corrected before initiating Increlex treatment. Limitations of use: Increlex is not a substitute to GH for approved GH indications. (2016) FDA Recommended Dosing Preprandial glucose monitoring is recommended at treatment initiation and until a well-tolerated dose is established. If frequent symptoms of hypoglycemia or severe hypoglycemia occur, preprandial glucose monitoring should continue. The dosage of Increlex should be individualized for each patient. The recommended starting dose of Increlex is 0.04 to 0.08 mg/kg (40 to 80 micrograms/kg) twice daily by subcutaneous injection. If well-tolerated for at least one week, the dose may be increased by 0.04 mg/kg per dose, to the maximum dose of 0.12 mg/kg given twice daily. Doses greater than 0.12 mg/kg given twice daily have not been evaluated in children with Primary IGFD and, due to potential hypoglycemic effects, should not be used. Increlex should be administered shortly before or after (± 20 minutes) a meal or snack. If the patient is unable to eat shortly before or after a dose for any reason, that dose of Increlex should be withheld. Subsequent doses of Increlex should never be increased to make up for one or more omitted doses. Drug Availability Increlex is supplied as a 10 mg per ml sterile solution in multiple dose glass vials (40 mg per vial). General Background Disease Overview IGF-I deficiency has also been called growth hormone insensitivity syndrome or growth hormone resistance syndrome. IGF-I deficiency was first described in a severe form, due to a block of growth hormone action at the level of the growth hormone receptor. As a consequence of this abnormal growth hormone receptor function, little IGF-I is produced. The ensuing severe IGF-I deficiency causes a type of growth failure that resembles the growth failure seen in patients with severe growth hormone deficiency. However, patients with severe IGF-I deficiency have normal concentrations of growth hormone. This primary form of severe IGF-I deficiency is differentiated from secondary forms of IGF-I deficiency or growth hormone insensitivity, caused by, for example, malnutrition, GH deficiency or hypothyroidism. (Backeljauw, 2014) Pharmacology Mecasermin contains recombinant deoxyribonucleic acid (DNA)-engineered human insulin-like growth factor-1 (rhigf-1). It is designed to replace natural IGF-1 in pediatric patients who are deficient, promoting normalized statural growth. Patients with severe primary IGF-1 deficiency (primary IGFD) fail to produce adequate levels of IGF-1, due to disruption of the growth hormone (GH) pathway used to promote IGF-1 release (possible GH pathway disruptions include mutations in the GH receptor [GHR], post-ghr signaling pathway, and IGF-1 gene defects). The active ingredient of mecasermin is identical to the natural hormone IGF-1, which the body normally produces in response to stimulation by GH. IGF-1 is the direct mediator of growth hormone's effect on statural growth and must be present in order for children's Page 3 of 5
4 bones, cartilage and organs to grow normally. Without adequate IGF-1, children cannot achieve a height within the normal range. (McEvoy, 2016) Severe primary IGFD can lead to a range of other metabolic disorders, including lipid abnormalities, decreased bone density, obesity, and insulin resistance. Mecasermin is the first product based on the IGF-1 protein approved by the FDA specifically indicated for the long-term treatment of growth failure in pediatric patients with Primary IGFD or with GH gene deletion who have developed neutralizing antibodies to GH. Mecasermin is not indicated to treat secondary IGFD resulting from GH deficiency, malnutrition, hypothyroidism or chronic treatment with pharmacologic doses of anti-inflammatory steroids. Thyroid and nutritional deficiencies should be corrected before initiating mecasermin treatment. Mecasermin is not a substitute for GH treatment. Mecasermin was approved as part of the FDA's orphan drug program, in which drugs designed to treat rare conditions or those with few available therapies are given expedited approval. (McEvoy, 2016) Guidelines Pediatric Endocrine Society The Pediatric Endocrine Society provides guidance regarding the use of IGF-1 therapy to increase height in patients with severe Primary Insulin-like Growth Factor Deficiency and administering IGF-1 20 minutes after a carbohydrate-containing meal or snack. In addition, the guideline recommends a trial of GH therapy before initiating IGF-1 for patients with unexplained IGF-1 deficiency. This recommendation, however, is not supported by clinical trial evidence. Patients with hormone signaling defects known to be unresponsive to GH treatment can start directly on IGFI replacement; these include patients with very low or undetectable levels of GHBP and/or proven GHR gene mutations known to be associated with Laron syndrome/ GHIS, GH-neutralizing antibodies, STAT5b gene mutations, and IGF1 gene deletion or mutation. (Grimberg, 2016) Clinical Efficacy FDA Approved Indications Approval of mecasermin was based on five clinical trials of the drug: four were open-label studies, and one was double-blind and placebo-controlled. The studies enrolled a total of 71 children suffering from extreme short stature; all children exhibited symptoms of Primary IGFD, including slow growth rates, low IGF-1 serum concentrations and normal growth hormone secretion. Data from these 5 clinical studies were pooled for a global efficacy and safety analysis. Baseline characteristics for the patients evaluated in the primary and secondary efficacy analyses were (mean, SD): chronological age (years): 6.7 ± 3.8; height (cm): 84.8 ± 15.3 cm; height standard deviation score (SDS): -6.7 ± 1.8; height velocity (cm/yr): 2.8 ± 1.8; height velocity SDS: -3.3 ± 1.7; IGF-1 (ng/ml): 21.6 ± 20.6; IGF-1 SDS: -4.3 ± 1.6; and bone age (years): 4.2 ± 2.8. Sixty-one subjects had at least one year of treatment. Fifty-three (87%) had Laron Syndrome; 7 (11%) had GH gene deletion, and 1 (2%) had neutralizing antibodies to GH. Thirty-seven (61%) of the Reference ID: subjects were male; forty-eight (79%) were Caucasian. Fifty-six (92%) of the subjects were prepubertal at baseline. Forty-nine subjects were included in an analysis of the effects of INCRELEX on bone age advancement. The mean ± SD change in chronological age was 4.9 ± 3.4 years and the mean ± SD change in bone age was 5.3 ± 3.4 years. An analysis of safety showed that long-term treatment with mecasermin has an acceptable safety profile and appears to be well tolerated. Side effects were mild to moderate in nature and included hypoglycemia (42%), tonsillar hypertrophy (15%) and intracranial hypertension (4%). Funduscopic examination is recommended at the initiation and periodically during the course of Increlex therapy. Experimental, Investigational, Unproven Uses Case series and randomized controlled trials have investigated mecasermin for several conditions, including the following: Autism Spectrum Disorder Bone loss associated with anorexia Phelan- McDermid syndrome Prevention of Retinopathy of Prematurity Page 4 of 5
5 Rett syndrome Amyotrophic Lateral Sclerosis (ALS) Coding/Billing Information Note: Increlex is typically covered under pharmacy benefit plans. Certain prescription drugs require an authorization for coverage to ensure that appropriate treatment regimens are followed. Medical drug coding and diagnosis codes, however, are generally not required for pharmacy claims submissions, therefore, this section is not in use. References 1. Backeljauw P, Dattani M, Cohen P, Rosenfeld R. Pediatric Endocrinology. 4th ed. Philadelphia, PA: Saunders Elsevier; 2014: Grimberg A, DiVall S, Polychronakos C, et al. On behalf of the Drug and Therapeutics Committee and Ethics Committee of the Pediatric Endocrine Society. Guidelines for Growth Hormone and Insulin- Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency. Horm Res Paediatr Nov 2016; 86: Ipsen Biopharmaceuticals, Inc., Increlex (mecasermin [rdna origin] injection) Product Information. Basking Ridge, NJ: Ipsen Biopharmaceuticals. March McEvoy GK, ed. AHFS 2016 Drug Information. Bethesda, MD: American Society of Health-Systems Pharmacists, Inc The registered marks "Cigna" and the "Tree of Life" logo are owned by Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include Connecticut General Life Insurance Company, Cigna Health and Life Insurance Company, Cigna Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. Page 5 of 5
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Mecasermin (Increlex) Reference Number: CP.PHAR.150 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Coding Implications Revision Log See Important
More informationCorporate Medical Policy
Corporate Medical Policy Treatment for Severe Primary IGF-1 Deficiency File Name: Origination: Last CAP Review: Next CAP Review: Last Review: treatment_for_severe_igf-1_deficiency 2/2006 7/2017 7/2018
More informationAETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Growth Hormone and related agents
Aetna Better Health 2000 Market Street, Suite 850 Philadelphia, PA 19103 AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Growth Hormone and related agents Revised April 2014 Growth
More informationCIGNA HealthCare Prior Authorization Form - Growth Hormone Medications -
Pharmacy Services Phone: (800)244-6224 Fax: (800)390-9745 CIGNA HealthCare Prior Authorization Form - Growth Hormone Medications - Notice: Failure to complete this form in its entirety may result in delayed
More informationGrowth Hormones DRUG.00009
Market DC Growth Hormones DRUG.00009 Override(s) Prior Authorization Quantity Limit Approval Duration WPM PAB Center: Thirty (30) day exception for recently expired (within the past 45 days) growth hormone
More informationAetna Better Health of Virginia
Genotropin Nutropin Serostim Zomacton Humatrope Omnitrope Zorbtive somatropin Norditropin Saizen General Criteria for Approval: Omnitrope vial formulation is the preferred Growth Hormone product; consideration
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen, Zomacton (aka. Tev-Tropin)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.12 Subject: Growth Hormone Pediatric Page: 1 of 6 Last Review Date: September 15, 2016 Growth Hormone
More informationCommittee Approval Date: January 19, 2015 Next Review Date: January 2016
Medication Policy Manual Policy No: dru126 Topic: Increlex, mecasermin Date of Origin: January 3, 2006 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: February
More informationGROWTH HORMONE THERAPY
GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below including FDA-approved
More informationCigna Drug and Biologic Policy
Cigna Drug and Biologic Policy Subject Collagenase clostridium histolyticum Effective Date... 11/15/2017 Next Review Date... 11/15/2018 Coverage Policy Number... 1021 Table of Contents Coverage Policy...
More informationGROWTH HORMONE THERAPY
GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 03/01/201804/01/2019 POLICY A. INDICATIONS The indications below including
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.11 Subject: Growth Hormone Adult Page: 1 of 6 Last Review Date: December 8, 2017 Growth Hormone Adult
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.11 Subject: Growth Hormone Adult Page: 1 of 6 Last Review Date: September 15, 2016 Growth Hormone
More informationGROWTH HORMONE THERAPY
GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 12/30/201601/01/2018TBD03/01/2018 POLICY A. INDICATIONS The indications
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Romiplostim Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date... 12/15/2017 Next
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other SOMATROPIN HUMATROPE GENOTROPIN NORDITROPIN NORDITROPIN FLEXPRO NORDITROPIN NORDIFLEX NUTROPIN NUTROPIN AQ OMNITROPE SAIZEN ZOMACTON 02824 BRAND ZORBTIVE BRAND SEROSTIM
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen, Zomacton
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.11 Subject: Growth Hormone Adult Page: 1 of 6 Last Review Date: September 20, 2018 Growth Hormone
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.11 Subject: Growth Hormone Adult Page: 1 of 6 Last Review Date: December 5, 2014 Growth Hormone Adult
More information2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization AETA BETTER HEALTH KETUCK Growth Hormone (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
Program Number 2018 P 1039-8 Program UnitedHealthcare Pharmacy Clinical Pharmacy Programs Prior Authorization/Notification Human Growth Hormone, Growth Stimulating Products Medication Human Growth Hormone:
More informationGrowth Hormone!gents. WA.PHAR.50 Growth Hormone Agents
Growth Hormone!gents WA.PHAR.50 Growth Hormone Agents Background: Human growth hormone, also known as somatotropin, is produced in the anterior lobe of the pituitary gland. This hormone plays an important
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Voriconazole Effective Date... 3/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 4004 Table of Contents Coverage Policy... 1 General Background...
More informationFirst Name. Specialty: Fax. First Name DOB: Duration:
Prescriber Information Last ame: First ame DEA/PI: Specialty: Phone - - Fax - - Member Information Last ame: First ame Member ID umber DOB: - - Medication Information: Drug ame and Strength: Diagnosis:
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject: Somatropin Table of Contents Coverage Policy...1 General Background...9 Coding/Billing Information... 12 References... 12 Effective Date.. 01/15/2018 Next
More informationGeneral Approval Criteria for ALL Growth Hormone agents: (ALL criteria must be met)
Growth Hormone Agents Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients Page 1 of 7 Preferred Agents Somatropin Pen (Norditropin ) Somatropin Pen (Nutropin AQ ) Non-Preferred
More information2. Is the request for Humatrope? Y N [If no, skip to question 6.]
Pharmacy Prior Authorization AETA BETTER HEALTH FLORIDA Growth Hormone Agents This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date.
More informationOriginal Effective Date: 7/5/2007
Subject: Recombinant Human Growth Hormone: PEDIATRIC_GENETIC DISEASES with Primary Effects on Growth Turner syndrome Noonan syndrome Prader-Willi syndrome SHOX mutations DISCLAIMER Original Effective Date:
More informationGROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY CHILD AND ADOLESCENT
1. Medical Condition TUEC Guidelines GROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY CHILD AND ADOLESCENT Growth Hormone Deficiency and other indications for growth hormone therapy
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 2016-8 Program Prior Authorization/Medical Necessity Medication Human Growth Hormone: Somatropin (Genotropin *, Humatrope *, Norditropin
More informationATHLETES & PRESCRIBING PHYSICIANS PLEASE READ
ATHLETES & PRESCRIBING PHYSICIANS PLEASE READ USADA can grant a Therapeutic Use Exemption (TUE) in compliance with the World Anti-Doping Agency International Standard for TUEs. The TUE application process
More informationAETNA BETTER HEALTH Prior Authorization guideline for Growth Hormone Agents
AETNA BETTER HEALTH Prior Authorization guideline for Growth Hormone Agents Growth Hormone and related agents Formulary: Omnitrope vials Non-Formulary: Genotropin, Humatrope, Saizen, Serostim, Tev-Tropin,
More informationGrowth Hormone Therapy
Growth Hormone Therapy Policy Number: Original Effective Date: MM.04.011 05/21/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/23/2014 Section: Prescription Drugs Place(s)
More informationTEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: HUMATROPE, NUTROPIN AQ, OMNITROPE, SAIZEN
TEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: HUMATROPE, NUTROPIN AQ, OMNITROPE, SAIZEN STEP 1: CLEARLY PRINT AND COMPLETE TO EXPEDITE PROCESSING Date: Prescriber First & Last Name:
More informationPolicy: Growth Hormones Reference Number: TCHP.PHAR.184 Effective Date: Last Review Date:
Policy: Growth Hormones Reference Number: TCHP.PHAR.184 Effective Date: 07.01.2018 Last Review Date: 04.13.2018 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Apremilast Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date... 1/1/2018 Next
More informationPrior Authorization Criteria Form This form applies to Paramount Commercial Members Only. Non-Preferred Growth Hormone Products
Prior Authorization Criteria Form This form applies to Paramount Commercial Members Only Criteria: P0078 Approved: 3/2017 Reviewed: Non-Preferred Growth Hormone Products Complete/review information, sign
More informationEffective September 30, 2011 Please refer to the Pharmacy policy for the new coverage criteria
Effective September 30, 2011 Please refer to the Pharmacy policy for the new coverage criteria Name of Policy: Growth Hormone and Insulin Like Growth Factor-1 (IGF-1) Analogues Policy #: 067 Latest Review
More informationOriginal Effective Date: 7/5/2007
Subject: Recombinant Human Growth Hormone (somatropin)_adult Growth Hormone Deficiency GHD HIV/AIDS-associated wasting and cachexia Short Bowel Syndrome (SBS) Policy Number: MCP-004-D Review Dates: 4/28/2010,
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Antiemetic Therapy Table of Contents Coverage Policy... 1 General Background... 6 Coding/Billing Information... 8 References... 8 Effective Date... 1/1/2018
More informationGenotropin, Norditropin, Nutropin, Nutropin AQ, Humatrope, Saizen,
Blue Cross Blue Shield of Vermont and The Vermont Health Plan Prior Approval Guidelines Human Growth Hormone Somatropin (Genotropin, Norditropin, Nutropin, Nutropin AQ, Humatrope, Serostim, Saizen, Zomacton/TevTropin,
More informationRequest for Prior Authorization Growth Hormone (Norditropin
Request for Prior Authorization Growth Hormone (Norditropin, Nutropin/AQ ) Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Growth Hormone require a
More informationPharmacy Management Drug Policy
SUBJECT: Policy POLICY NUMBER: Pharmacy-18 EFFECTIVE DATE: 08/03 LAST REVIEW DATE: 9/24/2018 If the member s subscriber contract excludes coverage for a specific service or prescription drug, it is not
More informationGROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY ADULT
1. Medical Condition GROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY ADULT Growth Hormone Deficiency and other indications for growth hormone therapy (adult). 2. Diagnosis A.
More informationPiloting Treatment with IGF-1 in Phelan-McDermid Syndrome
Piloting Treatment with IGF-1 in Phelan-McDermid Syndrome Seaver Autism Center for Research and Treatment at Mount Sinai Principal Investigator: Alex Kolevzon, MD One Gustave L. Levy Place, Box 1230 New
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Alpha1-Proteinase Inhibitors Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 5 References... 6 Effective Date...
More informationPharmacy Prior Authorization Growth Hormone- Clinical Guidelines
Genotropin, Humatrope, Norditropin, Nutropin, Omnitrope, Saizen, Serostim, somatropin, Zorbtive, Zomacton I. Growth Hormone Deficiency in Children and Adolescents: Note: Provider must submit chart notes
More informationATHLETES & PRESCRIBING PHYSICIANS PLEASE READ
ATHLETES & PRESCRIBING PHYSICIANS PLEASE READ USADA can grant a Therapeutic Use Exemption (TUE) in compliance with the World Anti- Doping Agency International Standard for TUEs. The TUE application process
More informationTEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: GENOTROPIN & NORDITROPIN Texas Children s Health Plan Only
TEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: GENOTROPIN & NORDITROPIN Texas Children s Health Plan Only STEP 1: CLEARLY PRINT AND COMPLETE TO EXPEDITE PROCESSING Date: Prescriber First
More informationClinical Policy: Somatropin (Recombinant Human Growth Hormone) Reference Number: CP.PHAR.55 Effective Date: 03/11 Last Review Date: 06/17
Clinical Policy: (Recombinant Human Growth Hormone) Reference Number: CP.PHAR.55 Effective Date: 03/11 Last Review Date: 06/17 Line of Business: Medicaid Revision Log See Important Reminder at the end
More informationRecombinant IGF-1 Therapy in Children with Severe Primary IGF-1 Deficiency (SPIGFD)
Recombinant IGF-1 Therapy in Children with Severe Primary IGF-1 Deficiency (SPIGFD) Formulated by the UK IGF-1 User s Group February 2015. Revised February 2018 by Dr Helen Storr, Centre for Endocrinology,
More informationCircle Yes or No Y N. [If yes, skip to question 30.] 2. Is this request for a child? Y N. [If no, skip to question 20.]
05/20/2015 Prior Authorization MERC CARE PLA (MEDICAID) Growth Hormone (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and
More informationReference ID:
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use INCRELEX safely and effectively. See full prescribing information for INCRELEX. INCRELEX (mecasermin
More informationHypothalamic & Pituitary Hormones
1 Hypothalamic & Pituitary Hormones Pharmacologic Applications: Drugs that mimic or block the effects of hypothalamic or pituitary hormones have the following applications: 1. Replacement therapy for hormone
More informationGrowth hormone therapy for short stature in adolescents the experience in the University Medical Unit, National Hospital of Sri Lanka
Growth hormone therapy for short stature in adolescents Growth hormone therapy for short stature in adolescents the experience in the University Medical Unit, National Hospital of Sri Lanka K K K Gamage,
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Interleukin (IL)-5 Antagonists: Mepolizumab and Reslizumab Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 5
More informationSubject Index. neuronal survival promotion by insulinlike growth factor-i , 162 regulatory proteins 148, 162
Subject Index Acid-labile subunit (ALS) evaluation 84 function 84 growth hormone activity marker 91 growth hormone insensitivity levels 102, 104 Alzheimer s disease, insulin-like growth factor-i neuroprotection
More informationClinical Guideline POSITION STATEMENT ON THE INVESTIGATION AND TREATMENT OF GROWTH HORMONE DEFICIENCY IN TRANSITION
Clinical Guideline POSITION STATEMENT ON THE INVESTIGATION AND TREATMENT OF GROWTH HORMONE DEFICIENCY IN TRANSITION Date of First Issue 01/04/2015 Approved 28/01/2016 Current Issue Date 28/01/2016 Review
More informationDISCLAIMER SUMMARY OF EVIDENCE/POSITION
Subject: Recombinant Human Growth Hormone Original Effective Date: 7/5/2007 (somatropin)_ PEDIATRIC Growth Hormone Deficiency Growth Failure in Children and Adolescents with Classic GHD [under 18 years]
More informationHUMAN GROWTH HORMONE GENOTROPIN
Drug Prior Authorization Guideline HUMAN GROWTH HORMONE GENOTROPIN (somatropin) PA9728 Covered Service: Yes when meets criteria below Prior Authorization Required: Yes Additional Information: Medicare
More informationStatement of Medical Necessity
Y E A R S (somatropin [rdna origin] for injection) Statement of Medical Necessity See inside cover for a list of documentation to accompany the Omnitrope Statement of Medical Necessity (SMN). Documentation
More informationPENS 2017 Minneapolis, MN April 27, Disclosure. Objectives: Growth Hormone Guidelines Roundtable
Growth Hormone Guidelines Roundtable PENS 2017 Minneapolis, MN April 27, 2017 Panelists: Mary S. Burr, DNP, CPNP-PC Catherine P. Metzinger, AAS, RN, CDE Bradley S. Miller, MD, PhD Disclosure Dr. Miller
More informationINCRELEX (mecasermin) injection, for subcutaneous use Initial U.S. Approval: 2005
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use INCRELEX safely and effectively. See full prescribing information for INCRELEX. INCRELEX (mecasermin)
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Omalizumab Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 6 References... 7 Effective Date... 3/15/2018 Next
More informationIn collaboration with the FDA, Ipsen will release a second batch of Increlex in September 2014
PRESS RELEASE Ipsen Announces Second Resupply of Increlex (mecasermin [rdna origin] Injection) in the U.S. in 2014 In collaboration with the FDA, Ipsen will release a second batch of Increlex in September
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Human Growth Hormone) Reference Number: CP.CPA.84 Effective Date: 11.16.16 Last Review Date: 05.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this
More informationDiagnosing Growth Disorders. PE Clayton School of Medical Sciences, Faculty of Biology, Medicine & Health
Diagnosing Growth Disorders PE Clayton School of Medical Sciences, Faculty of Biology, Medicine & Health Content Normal pattern of growth and its variation Using growth charts Interpreting auxological
More informationMonth/Year of Review: September 2013 Date of Last Review: September 2012
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights
More informationPFIZER INC. PROTOCOL TITLE: Efficacy and Safety of the Authentic Recombinant Human Somatropin Genotropin in Children with Familial Short Stature
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationPHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 4/1/19 SECTION: DRUGS LAST REVIEW DATE: 2/21/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
GROWTH HORMONE THERAPY: Genotropin (somatropin) subcutaneous injection Humatrope (somatropin) subcutaneous injection Norditropin (somatropin) subcutaneous injection Nutropin AQ (somatropin) subcutaneous
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Human Growth Hormone Page 1 of 57 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Human Growth Hormone Pre-Determination of Services IS REQUIRED by the Member s
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Human Growth Hormone Page 1 of 44 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Human Growth Hormone Pre-Determination of Services IS REQUIRED by the Member s
More informationPHARMACY POLICY STATEMENT Indiana Medicaid
DRUG NAME BILLING CODE BENEFIT TYPE SITE OF SERVICE ALLOWED COVERAGE REQUIREMENTS LIST OF DIAGNOSES CONSIDERED NOT MEDICALLY NECESSARY PHARMACY POLICY STATEMENT Indiana Medicaid Norditropin (somatropin)
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Nusinersen Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 5 References... 5 Effective Date... 10/15/2017 Next
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Belimumab Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date... 11/15/2017 Next
More informationElements for a Public Summary
Page 3 of 7 VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Growth hormone deficiency occurs when the pituitary gland does not produce enough growth hormone.. Growth hormone
More informationR ecombinant growth hormone (GH) treatment is recommended
126 ORIGINAL ARTICLE The investigation of short stature: a survey of practice in Wales and suggested practical guidelines C Evans, J W Gregory, on behalf of the All Wales Clinical Biochemistry Audit Group...
More informationStaff-Assisted Home Hemodialysis
Medical Coverage Policy Staff-Assisted Home Hemodialysis Table of Contents Coverage Policy... 1 Overview... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date...11/15/2017
More informationDR. SHAHJADA SELIM. Growth Hormone Deficiency. Subdivisions of Growth Hormone Deficiency. General Discussion. Signs & Symptoms
Growth Hormone Deficiency NORD gratefully acknowledges Joe Head, NORD Intern and Richard A. Levy, MD, Director of Pediatric Endocrinology Section, Rush University, for their assistance in the preparation
More informationHorm Res Paediatr DOI: /
HORMONE RESEARCH IN PÆDIATRIC S Clinical Practice Committee Publication Received: July 15, 2016 Accepted: September 30, 2016 Published online: November 25, 2016 Guidelines for Growth Hormone and Insulin-Like
More informationPHARMACY POLICY STATEMENT Indiana Medicaid
DRUG NAME BILLING CODE BENEFIT TYPE SITE OF SERVICE ALLOWED COVERAGE REQUIREMENTS LIST OF DIAGNOSES CONSIDERED NOT MEDICALLY NECESSARY PHARMACY POLICY STATEMENT Indiana Medicaid Zomacton (somatropin) Must
More informationClinical Policy: Pasireotide (Signifor LAR) Reference Number: CP.PHAR.332 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Signifor LAR) Reference Number: CP.PHAR.332 Effective Date: 03.01.17 Last Review Date: 11.17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Transmucosal Fentanyl Effective Date... 4/15/2018 Next Review Date... 4/15/2019 Coverage Policy Number... 1018 Table of Contents Coverage Policy... 1 General
More informationGrowth Hormone Deficiency and Related Diagnoses
Care1st Health Plan Arizona, Inc. Easy Choice Health Plan Harmony Health Plan of Illinois Missouri Care Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona OneCare (Care1st Health
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationGrowth Hormone Review 04/19/2010
Review 04/19/2010 Copyright 2004-2010 by Provider Synergies, L.L.C. All rights reserved. Printed in the United States of America. All rights reserved. No part of this publication may be reproduced or transmitted
More informationMEDICAL POLICY I. POLICY HUMAN GROWTH HORMONE MP POLICY TITLE POLICY NUMBER
g Original Issue Date (Created): July 1, 2002 Most Recent Review Date (Revised): March 25, 2014 Effective Date: June 1, 2014 I. POLICY Recombinant human growth hormone (GH) therapy may be considered medically
More informationClinical Policy: Thryoid Hormones and Insulin Testing in Pediatrics Reference Number: CP.MP.154
Clinical Policy: Thryoid Hormones and Insulin Testing in Pediatrics Reference Number: CP.MP.154 Effective Date: 12/17 Last Review Date: 12/17 See Important Reminder at the end of this policy for important
More informationGrowth IGF Analyte Information
Growth IGF-1 Analyte Information - 1 - IGF-1 Introduction Insulin-like growth factor 1 (IGF-1, IGF-I) is a single chain polypeptide containing 70 amino acids and three disulfide bridges. It is structurally
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Edaravone Table of Contents Coverage Policy... 1 FDA Approved Indications... 2 General Background... 2 Coding/Billing Information... 5 References... 5 Effective
More informationCaretropin. Daewoong Recombinant Human Growth Hormone. Recombinant Escherichia coli. Growth hormone deficiency
Caretropin Daewoong Recombinant Human Growth Hormone Active ingredient Host cell Indication Formulation Administration Somatropin Recombinant Escherichia coli Growth hormone deficiency 1. Lyophilized powder
More informationThis Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only.
This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only. GROWTH HORMONE THERAPY POLICY Omnitrope is the EXCLUSIVE growth hormone covered if patient meets criteria. COVERAGE
More informationGrowth Hormone plus Childhood Low- Dose Estrogen in Turner s Syndrome. N Engl J Med 2011;364: Present by R5 郭恬妮
Growth Hormone plus Childhood Low- Dose Estrogen in Turner s Syndrome N Engl J Med 2011;364:1230-42. Present by R5 郭恬妮 Introduction Turner s syndrome : partial or complete X-chromosome monosomy, 1 in 2000
More informationIdaho DUR Board Meeting Minutes
Idaho DUR Board Meeting Minutes Date: Jan. 16, 2014 Time: 9am-1pm Location: Idaho Medicaid, 3232 Elder Street, Boise, Idaho, Conference Room D-West Moderator: Mark Turner, M.D. Committee Member Present:
More informationSOMATROPIN ( Genotropin, Humatrope, Norditropin,
Shared Care Guidelines DRUG: SOMATROPIN ( Genotropin, Humatrope, Norditropin, Saizen and Omnitrope ) (Adults) Introduction: Indication: Growth hormone deficiency in adults Dosage & administration: 150-300
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Human Growth Hormone) Reference Number: CP.PHAR.55 Effective Date: 03.11 Last Review Date: 05.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Human Growth Hormone) Reference Number: CP.PHAR.55 Effective Date: 03.11 Last Review Date: 05.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this
More information